98%
921
2 minutes
20
Artificial intelligence (AI) is transforming multidisciplinary oncology at an unprecedented pace, redefining how clinicians detect, classify, and treat cancer. From earlier and more accurate diagnoses to personalized treatment planning, AI's impact is evident across radiology, pathology, radiation oncology, and medical oncology. By leveraging vast and diverse data-including imaging, genomic, clinical, and real-world evidence-AI algorithms can uncover complex patterns, accelerate drug discovery, and help identify optimal treatment regimens for each patient. However, realizing the full potential of AI also necessitates addressing concerns regarding data quality, algorithmic bias, explainability, privacy, and regulatory oversight-especially in low- and middle-income countries (LMICs), where disparities in cancer care are particularly pronounced. This study provides a comprehensive overview of how AI is reshaping cancer care, reviews its benefits and challenges, and outlines ethical and policy implications in line with ASCO's 2025 theme, We offer concrete calls to action for clinicians, researchers, industry stakeholders, and policymakers to ensure that AI-driven, patient-centric oncology is accessible, equitable, and sustainable worldwide.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1200/EDBK-25-100048 | DOI Listing |
J Clin Ultrasound
September 2025
Division of Pediatric Surgery, Federico II University Hospital, Naples, Italy.
Paratesticular rhabdomyosarcoma (RMS) is a rare pediatric malignancy often misdiagnosed as benign conditions like epididymitis. We report a 4-year-old boy with paratesticular RMS and retroperitoneal metastasis, initially mistaken for epididymitis. The diagnostic delay resulted in disease progression, necessitating radical inguinal orchiectomy, hemiscrotectomy, and complete multimodal therapy.
View Article and Find Full Text PDFRev Recent Clin Trials
September 2025
Department of Radiation Oncology, University Hospital of Iraklion, 71110, Iraklion, Greece.
Introduction: Radiotherapy (RT) is an integral component of various multidisciplinary treatment approaches for pelvic malignancies, used both in the radical and adjuvant setting. Despite the improvement of radiotherapy modalities, pelvic radiotherapy often induces permanent erectile dysfunction (ED). However, post-treatment ED receives little medical attention, since patient follow-up focuses mainly on cancer recurrence surveillance.
View Article and Find Full Text PDFExp Clin Transplant
August 2025
>From the Department of Medical Oncology, Baskent University Faculty of Medicine, Ankara, Türkiye.
Objectives: Hepatocellular carcinoma is the fourth leading cause of cancer-related mortality worldwide, and almost all patients have simultaneous cirrhosis. For patients with hepatocellular carcinoma concurrent with cirrhosis, the best treatment option is liver transplant. With expansion of transplant criteria and increased use of liver transplant for treatment, median survival and recurrence rates in patients with hepatocellular carcinoma have also increased.
View Article and Find Full Text PDFNat Aging
September 2025
Aging Biomarker Consortium (ABC), Beijing, China.
The global surge in the population of people 60 years and older, including that in China, challenges healthcare systems with rising age-related diseases. To address this demographic change, the Aging Biomarker Consortium (ABC) has launched the X-Age Project to develop a comprehensive aging evaluation system tailored to the Chinese population. Our goal is to identify robust biomarkers and construct composite aging clocks that capture biological age, defined as an individual's physiological and molecular state, across diverse Chinese cohorts.
View Article and Find Full Text PDFJ Cancer Res Clin Oncol
September 2025
Department of Surgery, Mannheim School of Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Purpose: The study aims to compare the treatment recommendations generated by four leading large language models (LLMs) with those from 21 sarcoma centers' multidisciplinary tumor boards (MTBs) of the sarcoma ring trial in managing complex soft tissue sarcoma (STS) cases.
Methods: We simulated STS-MTBs using four LLMs-Llama 3.2-vison: 90b, Claude 3.